Profile picture of medscape.com
Nonalcoholic Steatohepatitis: Mission Possible!: Learn to recognize, diagnose, and manage nonalcoholic steatohepatitis (NASH) and metabolic ...
medscape.org/viewarticle/998939
Nonalcoholic Steatohepatitis: Mission Possible!
Profile picture of medscape.com
❓ Treatment decisions can be challenging for steatotic liver disease. How do you compare with the experts? ms.spr.ly/6189ib0uz
Profile picture of CNBC
Hedge funds are betting against these stocks the most in this sell-off: These stocks made the cut for high short interest from the end of August through the ...
cnbc.com/2023/09/28/hedge-funds-are-betting-against-these-stocks-the-most-in-this-sell-off.html
Hedge funds are betting against these stocks the most in this sell-off
Profile picture of Investor's Business Daily
This Top Stock, With 159% Growth, Just Surged For A Second Day: Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay liver-disease ...
investors.com/news/technology/cbay-stock-how-cymabay-with-huge-growth-this-year-is-taking-on-intercept-genfit/
This Top Stock, With 159% Growth, Just Surged For A Second Day
Profile picture of Insider (news website)
Madrigal's NASH drug reports positive results, stock jumps: Madrigal Pharmaceuticals reported positive results for its treatment for NASH ...
businessinsider.com/madrigals-nash-drug-reports-positive-results-stock-jumps-2022-12
Madrigal's NASH drug reports positive results, stock jumps
Profile picture of Barron's
Intercept Will Ask Yet Again for FDA to Approve Its NASH Drug: A newly identified condition thought to affect many adults in Western countries ...
barrons.com/articles/intercept-nash-drug-fda-stock-51657293097
Intercept Will Ask Yet Again for FDA to Approve Its NASH Drug